In the context of current U.S. racial justice movements, analysis of racism in medicine within medical education is a critical task for all institutions. To educate the next generation of physicians about racism in medicine and out of concern that the curriculum required critical assessment and change, a group of students and faculty at Boston University School of Medicine (BUSM) initiated a longitudinal curricular analysis through a vertical integration group, commissioned by the Medical Education Committee, from May 2019 to June 2020. The curriculum analysis and the major outcomes and guiding principles that emerged from it are described as a path forward, toward a more inclusive curriculum. The major elements of this analysis included a comprehensive internal curricular assessment and an external assessment of peer institutions that led to the development of key curricular recommendations and overarching equity and specific racially focused equity competencies. The curricular recommendations fall into the following domains: (1) challenging the persistence of biological/genetic notions of race, (2) embedding structural practices in medical education to dismantle racism in medicine, and (3) promoting institutional climate change. Initial steps to implement these recommendations are described. The authors believe that the historic and present reality of racism in America and in medicine has impacted medical education specifically, and more broadly, the practice of medicine, trainee experience, and patient outcomes. The key findings of the BUSM analysis are transferable to other medical education institutions, and the described review process can support peer institutions as they engage in the imperative work of institutional reflection and addressing the salient ideas and practices that uphold racism in medicine.

Background: While recent vaccine development has initiated a return to pre-COVID "normalcy" both in the dermatology clinic and worldwide, significant challenges remain regarding the public’s willingness to receive a COVID-19 vaccine. Dermatologists often discuss vaccinations with their patients and aid them in making evidence-based medical decisions. Previous studies have looked at the U.S. population’s willingness to receive a COVID-19 vaccine, but no studies have examined the dermatology patient population from an urban, safety-net hospital. Studies have shown that understanding the target audience is the first step towards increasing vaccine acceptance. Methods: A cross-sectional, telephone-based survey study was administered to 326 patients of an urban, safety-net hospital from July 2020 to August 2020 in order to assess willingness to obtain a COVID-19 vaccine. Results: Our survey study showed that 57.7% of patients with a recent dermatology appointment are willing to receive a COVID-19 vaccine and that safety concerns represent the main reason for patient hesitancy. Patients who do not regularly receive a flu vaccine, non-Caucasian patients, and those who know someone who tested positive for COVID-19 are less willing to receive a COVID-19 vaccine. Patients with a recent dermatology appointment are more willing to receive a COVID-19 vaccine than those who did not have a recent dermatology appointment. Conclusions: Our results provide dermatologists, especially those working in urban safety-net clinics, with key information about the attitude of patients toward the COVID-19 vaccine.

Infantile food products have been at the forefront of litigation in the recent year for unsafe standards set forth by their developing companies. This recent case development explores how the Court decided on a suit brought forth against Gerber for toxic levels of heavy metals in their food. Their opinion shines a light on how upcoming larger cases against Abbott Industries for unsafe milk products might be handled. The author urges the Courts and the FDA to work together to resolve these cases in the interest of pediatric public health.